Home > Boards > US OTC > Biotechs >

Bio-Matrix Scientific Group Inc. (BMSN)

Add BMSN Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator vegasdrummer, stockchaser64, The PoPo, Dr V, Chicago, Supraflyy37
Search This Board:
Last Post: 4/20/2014 12:47:12 AM - Followers: 1064 - Board type: Free - Posts Today: 3

(Majority-Owned Susidiary of BMSN)

Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN)
is a biotechnology company focused on identifying undervalued regenerative medicine applications
in the stem cell space and rapidly advancing these technologies through pre-clinical andPhase I/ II clinical trials.

Stem Cell Medicine


"Our business model is to acquire and form companies around
undervalued assets identified froma highly focused analysis of issued
patents in regenerative medicinethat have demonstrated proof of 


Dr. Ichim is one of the leading authorities in the
world on stem cell bi


With an emphasis on stem cell regenerative medicine


Our Business Model | Regen BioPharma

our business model 

Regen BioPharma has assessed over 20,000 stem cell related issued patents, narrowed down to 2000 patents with commercial applicability, and further identified 30 patents available for licensing. The company seeks to inlicense, take the product to, and through clinical safety and efficacy "signal" and spin out technologies.



Our Approach | Regen BioPharma




      In the "Conventional Model", stem cell companies are started with one basic technology, infrastructure is developed around that                       technology, then if the technology fails, significant resources are lost that have been used in the product-specific development

             Conventional Model
conventional model

             Regen BioPharma Model
regen model

Operational Plan

Month 1-2: Assembly of Team:
Regen intends to assemble a team of world-class leaders in the spheres of Technology, Intellectual Property assessment, valuation and Clinical development. Regen will seek to compile a team of Physician-Scientists with experience in the area of clinical trials for regenerative medicine/stem cell products, Regulatory experts who have successfully taken products through the FDA and corresponding agencies internationally, and Biotech Entrepreneurs who have track records of excellence in business formation and value optimization. -DONE
Month 1-4: Inlicensing of Intellectual Property:
The Company having already assessed over 20,000 issued patents and havingcompiled a shortlist of 30 targets; Regen will seek to execute licensing deals on an initial core of 3 technologies. Regen focuses onissued patents that have already passed preclinical studies but are not under clinical development. -DONE
Month 3-6: Interaction with Regulatory Agencies:
Regen intends to develop data packages for each of the technologies andinitiate interaction with Regulatory Agencies such as the FDA for initiation of trials.-DONE
Month 6-18: Clinical Implementation:
Regen intends to launch clinical trials with world-leading institutions to obtain human safety data and "signal" of therapeutic efficacy.  NEXT UP
Month 18-24: Exit:
It is intended that technologies "incubated" by Regen will be spun off either as separate companies, or sold to Large Pharma companies seeking to enhance their therapeutic pipeline.

"At present there exists a wealth of intellectual property that is 'collecting dust' in the corridors of Academia. Given the field of regenerative medicine and stem cell therapy is so young, and the business models are fuzzy at best in terms of valuation, we see this space as a unique opportunity for acceleration of clinical development/value optimization," said Bio-Matrix Chairman & CEO David Koos about its Regen BioPharma. "Valuations for stem cell companies that have passed the threshold of clinical safety, with signals of efficacy are astronomical. The $1.8 billion Mesoblast-Cephalon deal, as well as recent financings of private companies with as little as 3 patient data such as Promethera ($31 million) or Allocure with 16 patients ($23 million), is testimony to the extremely high valuations that are characteristic of this space."


Regen BioPharma Pipeline

HemaXellerate I™ FDA FILING
[Regen BioPharma filed an Investigational New Drug (IND) Application on February 5th, 2013.  Regen BioPharma is currently conducting additional safety tests requested by the FDA and anticipates completion of all requests from the FDA by March 2014 ]

HemaXellerate I is a cellular therapy designed to heal damaged bone marrow. HemaXellarate I utilizes a collection of cells harvested from the patient’s own adipose (fat) tissue to repair damaged bone marrow and stimulate production of blood cells . The initial application of HemaXellerate I will be the treatment of severe aplastic anemia, a rare and serious condition in which the bone marrow fails to make enough blood cells: red blood cells, white blood cells, and platelets. In practice, the physician is shipped a kit, which is used to collect adipose tissue. The tissue is sent to a processing facility, and a standardized cellular product is delivered in a ready-to-use manner for administration into the patient intravenously.

**The Company intends to seek Orphan Drug Designation under the Orphan Drug Act of 1983 from the US Food and Drug Administration for HemaXellerate I**

[Regen BioPharma is currently in the preclinical stage of development for dCellVax and plans to file an Investigational New Drug Application by March 2014]

The dCellVax therapeutic product is based on extracting blood from patients, growing a specialized type of immune cell from the blood called the "dendritic cell" and then subsequently genetically modifying the dendritic cell to become resistant to cancer's immune suppressive activity. It is known that cancer modifies the immune system by producing proteins which result in immune suppression. One such protein which cancer stimulates is an enzyme, indolamine 2,3 deoxygenase (IDO), which cancer turns on in dendritic cells. While dendritic cells are usually immune stimulators, dendritic cells found in cancer patients suppress the immune system as a result of expressing IDO.

The dCellVax therapeutic product uses patents that Regen BioPharma has in-licensed from Dr. Wei-Ping Min coupled with patents in-licensed from Benitec BioPharma.  By utilizing methods covered in both of these patents Regen BioPharma hopes to develop an immune-based, non-toxic cancer treatment initially targeting breast cancer.

HemaXellerate II™
[Regen BioPharma is currently in the preclinical stage of development for HemaXellerate II]

HemaXellerate II is intended to be a universal donor endothelial cell based therapeutic and is intended to be manufactured by obtaining cells from a part of the placenta called the “vascular lobules”. The cells are processed and utilized for the purpose of stimulating bone marrow hematopoetic stem cell repair and proliferation. The mechanism of action for HemaXellerate II is similar to HemaXellerate I whereby the harvested and processed cells would produce growth factors which would mediate the therapeutic effects of the product.


Managent Team | Regen BioPharma

David R. Koos, PhD, DBA

Chairman and Chief Executive Officer

David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 26 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or co-authored several peer reviewed journal articles primarily on biotechnology related subjects.

Thomas E. Ichim, PhD

Chief Scientific Officer and Board Member

Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. Dr. Ichim is a member of Vendevia Group, an innovative venture development organization focused on optimization of value in biotechnology ventures. He is scientific advisor to Orcrist Bio, Entest, and MBVaX. To date he has published 91 peer-reviewed articles and is co-editor of the textbook “RNA Interference: From Bench to Clinical Translation”. Ichim is an ad-hoc editor and sits on several editorial boards. Ichim is inventor on over 30 patents and patent applications. CV


Advisory Board | Regen BioPharma

Weiping Min, M.D.

Dr. Min is Associate Professor, Department of Surgery at the University of Western Ontario. His clinical research is focused on using siRNA to inhibit disease modalities, including cancer and organ rejection. He earned graduate and medical degrees from Nanchang University Medical School and the Ph.D. degree from Kyushu University.

David James Graham White, M.D., Ph.D.

Dr. White is a member of the Surgery and Immunology faculty of The Schulic School of Medicine, University of Western Ontario. He is one of the leading experts on using regenerative medicine transplant procedures to treat pancreatic conditions, including diabetes. He is also the Chief Scientific Officer of Sernova Corp and was formerly a Therapeutic Area Head for Novartis. He received the B.Sc. degree from the University of Surrey and the M.D. and Ph.D. degrees from Cambridge University.

David A. Suhy, PhD

Dr Suhy has a long-term interest in development of shRNA based therapeutics to treat human diseases. He is in the unique position of seeing of directing the research of a RNAi-based therapeutic from its earliest inception until it reaches clinical trials. Development of a shRNA therapeutic against the Hepatitis C virus (HCV) was initiated at Avocel in 2003. Financial constraints caused the company to shutter research operations in 2006.Upon raising venture capital, Tacere Therapeutics acquired the rights to the HCV family of drugs and brought back Dr. Suhy to head the program. Partnered with Pfizer shortly thereafter, this drug is their first foray into gene therapy-based approaches and is the first shRNA program partnered with a large pharma. Given Pfizer’s lack of experience in both areas, Dr. Suhy has played a pivotal role in its development as Tacere has continued to lead the research efforts for advancement of this product into the clinic and has stood side-by-side with Pfizer through all of the regulatory agency meetings.


Current Business Partners | Regen BioPharma





                        News and Recent Press Releases:

03/06/2014 14:53 Bio-Matrix Scientific Group Inc. Announces Dividend Record Date to Receive Shares in Subsidiary, Regen BioPharma, Inc.
12/11/2013 09:35 Regen BioPharma Announces HemaXellerate I (TM) Efficacy Data in Animal Model of Aplastic Anemia

10/31/2013 11:35 Bio-Matrix Scientific Group's Regen BioPharma Retains Cook General Biotechnology for Contract Manufacturing of HemaXellerate I
10/09/2013 15:11 Bio-Matrix Scientific Group Inc. Announces 20 Million Share Regen BioPharma Dividend to Be Paid to Shareholders
09/26/2013 08:00 Bio-Matrix Scientific Group's Subisidiary Regen BioPharma Enters Into Preclinical Trials Agreement for HemaXellerate I..
09/25/2013 08:30 Bio-Matrix Scientific Group's Subsidiary Regen BioPharma Announces dCellVax Breast Cancer Immunotherapeutic Product
09/17/2013 10:06 Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
08/16/2013 13:47 Bio-Matrix Scientific Group Discusses Regen BioPharma's Cancer Immunotherapy Program
08/08/2013 09:47 Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
07/31/2013 14:36 Bio-Matrix Scientific Group Provides Update on Its Regen BioPharma's HemaXellerate I (TM) Clinical Program
06/07/2013 08:30 Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program
05/06/2013 08:30 Bio-Matrix Scientific Group's Regen BioPharma Acquires Cancer Vaccine Technology With Initial Focus on Breast Cancer
04/04/2013 16:09 Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development
03/18/2013 09:57 Regen BioPharma Receives IND # From FDA for HemaXellerate
02/26/2013 10:12 Bio-Matrix Scientific Group's Regen BioPharma Executes LOI to Acquire Issued US Patent Covering Cancer Gene-Silencing...
02/05/2013 10:35 Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I (TM) Stem Cell Drug For Aplastic...
01/24/2013 14:53 Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate (TM) Bone Marrow Failure Product



(Majority-Owned Susidiary of BMSN)


Entest BioMedical Inc.(OTCQB: ENTB) develops immuno-therapeutic treatments that address illnesses and maladies in both veterinary and human medicine.  Of specific interest to us are immunological vaccines for oncology (cancer vaccines) and veterinary clinic acquisitions.  The basis for the majority of our approaches is underpinned by leveraging the body's own reparative / immunological mechanisms - as opposed to using toxic chemicals.

Areas of Focus
Currently, Entest is focused on significant therapeutic therapies that show promise for the development of under-served market niches with potential high demand.


BMSN Transfer Agent:
Securities Transfer Corporation

2591 Dallas Parkway Suite 102

Frisco, Texas 75034

Phone - 469-633-0101

FAX 469-633-0088

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
BMSN News: Bio-Matrix Scientific Group Inc. Announces Dividend Record Date to Receive Shares in Its Subsidiary Regen BioPharma, Inc. 03/06/2014 02:53:06 PM
BMSN News: Regen BioPharma Announces HemaXellerate I(TM) Efficacy Data in Animal Model of Aplastic Anemia 12/11/2013 09:35:00 AM
#129144  Sticky Note ~ BMSN = 2 Charts = Death~Cross~Coming!! :-( 1-eye-jack 04/17/14 01:24:05 PM
#128799  Sticky Note The problem is there is no one on Angry Goat 04/15/14 01:27:59 PM
#128451  Sticky Note BMSN/Regen Synopsis Dr V 04/13/14 08:02:25 AM
#121600  Sticky Note Updated BMSN/Regen BioPharma Timeline for IND Approval According The PoPo 03/24/14 01:14:31 PM
#129429   Good Question! I'm excited to find out. VvAngelvV 04/20/14 12:47:12 AM
#129428   What will the shareprice of BMSN do when sante1 04/20/14 12:40:11 AM
#129427   'V', thanks for the rectification. By this time sante1 04/20/14 12:29:43 AM
#129426   Nice catch Sage !! dmort545 04/19/14 10:19:50 PM
#129425   Wow! Thank you... I believe it Peacefulwendy 04/19/14 10:10:46 PM
#129424   A sentence adverbial is simply an adverb (modifies Sage7243 04/19/14 08:58:29 PM
#129423   International patent application has been published in WIPO cazual 04/19/14 07:53:01 PM
#129422   Sage, for the layman, can you explain what Peacefulwendy 04/19/14 07:02:29 PM
#129421   Can someone explain the second link? It Peacefulwendy 04/19/14 06:59:58 PM
#129420   .015 end of April.... .03 mid-May... >.20 once makecents99 04/19/14 06:22:29 PM
#129419   Strikingly, Responders (n=3) differed from nonresponders (n=8) in Sage7243 04/19/14 06:06:18 PM
#129418   .015 by EOD they announce FDA approval. Princetofu 04/19/14 05:37:52 PM
#129416   another delete massage for ohmyohmy 04/19/14 05:33:50 PM
#129415   .015 by end of may ahall 04/19/14 05:21:09 PM
#129414   Thanks Caz, that is a huge find. Longs sizzleweed 04/19/14 03:59:36 PM
#129411   Excellent post Dr V! Your vision of the Rk3 04/19/14 12:20:22 PM
#129409   BMSN $$$$ This is awesome! cazual 04/19/14 12:16:20 PM
#129408   WHO SAID BMSN IS HAVING A R/S? THAT'S BS vegasdrummer 04/19/14 11:59:53 AM
#129407   Question aboard, IF the r/s ohmyohmy 04/19/14 10:27:25 AM
#129406   I agree, but I think the MM's will Bare1 04/19/14 09:20:30 AM
#129405   Nice rebuttal, however to correct a couple of Dr V 04/19/14 08:32:40 AM
#129404   GM to all, I want to wish everyone LL1truth 04/19/14 08:21:55 AM
#129403   So correct, A RS would have been done 02tampabay 04/19/14 04:07:29 AM
#129402   People have to make the decision to be billygoat993 04/19/14 02:29:58 AM
#129401   This is by no means a stock to d5wr59mfi8 04/19/14 01:47:58 AM
#129400   Yes, the patent for dCellVax was approved on d5wr59mfi8 04/19/14 01:44:10 AM
#129399   Not worth the time to sit your money DRhos 04/19/14 01:38:00 AM
#129398   Has this been posted by anyone? Seems interesting. billygoat993 04/19/14 01:28:29 AM
#129397   If that should be the case , Koos sante1 04/19/14 01:15:22 AM
#129391   lt will trade side ways if nothing comes manjensen 04/18/14 09:28:23 PM
#129389   Spot on!! Member mark for you. Bare1 04/18/14 08:14:24 PM
#129388   Well I'm definitely not waiting till next year. the Beek 04/18/14 07:58:57 PM
#129379   You talk about "signs" you have and "info" Goldstrike 04/18/14 06:49:24 PM
#129377   You got to be joking,that decision is years brucebill 04/18/14 06:44:49 PM
#129376   Well worth re-reading. Spot on... Goldstrike 04/18/14 06:44:31 PM
#129374   link please? need a source for a trazbull 04/18/14 06:07:55 PM
#129372   BMSN STOCK lots of concern here about a stockchaser64 04/18/14 05:50:41 PM
#129369   I agree you Bare1, This thing will explode rocket999 04/18/14 04:50:37 PM
#129367   Yes this thing is gonna explode. Bare1 04/18/14 04:25:47 PM
#129365   BMSN has no R/S filed or even MENTIONED Dr V 04/18/14 04:10:18 PM
#129364   BMSN has ANSWERS not questions. No OUTSTANDING issues Dr V 04/18/14 04:07:32 PM
#129363   If a r/s should happen, ohmyohmy 04/18/14 04:06:44 PM
#129361   Anyone who does their DD properly knows that d5wr59mfi8 04/18/14 03:47:29 PM
#129358   BMSN STOCK look like a R/S could happen stockchaser64 04/18/14 03:15:49 PM
#129357   Ahhhhh, a full 5 days next week to angelicsatan666 04/18/14 03:08:54 PM
#129356   BMSN STOCK could have a rough week next stockchaser64 04/18/14 03:07:24 PM
#129355   Nice post V, great insight to the timing d5wr59mfi8 04/18/14 02:58:51 PM
#129354   Right on the money Dr. V! This is mrMando 04/18/14 12:53:18 PM
#129353   Load it up to the brim, brother. Wish Dr V 04/18/14 12:51:17 PM
#129352   Great post Dr. V - I agree totally. Bare1 04/18/14 12:12:50 PM